As we age, our brains change in ways that make them more vulnerable to damage. A recent look at mouse models shows that aging shifts how two key immune cells talk to each other. These cells are microglia and T cells. They live in the brain and help it heal or hurt it depending on the situation. The review found that aging changes the signals these cells send. This shift pulls in a specific type of T cell called CD8+ T cells. These cells arrive because of chemical messages called cytokines. Their presence can be harmful to the brain. They also change how other brain cells behave. Specifically, they cause myelin to become unstable. Myelin is the protective coating around nerve fibers. Without it, nerves cannot send signals well. The review also noted that this process limits the brain's ability to repair itself. This happens because the new immune cells trigger changes in glial cells. These changes create a state that resists healing. This is a serious problem for conditions like multiple sclerosis. In those diseases, the brain tries to fix damaged nerves but often fails. The findings come from studying mice, not humans. We must remember this is a review of existing data. It does not report new experiments or patient numbers. The evidence is based on what scientists have already published. While the results are clear for mice, we do not know exactly how this applies to people yet. The science is still growing. We need more research to understand if this happens in human brains. Until then, the story of aging immune cells remains a warning sign for nerve health.
Aging changes brain cells and invites immune cells that hurt nerve repair
Photo by National Institute of Allergy and Infectious Diseases / Unsplash
What this means for you:
Aging alters brain cell signals and invites immune cells that damage myelin and stop nerve repair in mouse models. More on Multiple Sclerosis
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS High-dose ocrelizumab did not further reduce disability progression in multiple sclerosis patients
· May 30, 2026
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
· May 30, 2026
Narrative review discusses MS continuum concepts for high-risk individuals New review suggests viewing MS as a continuum helps monitor those at higher risk
Frontiers · May 28, 2026
Network meta-analysis finds acupoint stimulation may improve function and fatigue in multiple sclerosis Acupuncture Shows Promise for Multiple Sclerosis Symptoms
Frontiers · May 26, 2026